secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0000950170-24-118344
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion reports Q3 net loss of $32.8M; FDA lifts clinical hold on diabetes trials
--------------------------------------------------------------------------------

- Cash and cash equivalents $88.3M as of Sep 30, 2024, down from $177.2M at Dec 31, 2023.
- Net loss $32.8M for Q3 2024 vs $28.4M same period 2023; includes $4.7M stock-based comp.
- FDA lifted clinical hold on COVALENT-111 (type 2 diabetes) and COVALENT-112 (type 1 diabetes) trials.
- Topline Week 26 data for both trials expected in December 2024.
- Announced third clinical candidate BMF-650 (oral GLP-1 RA); preclinical data to be shared Oct 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000095017024118344/0000950170-24-118344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000095017024118344/bmea-20241029.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-118344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer